This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Pure Tech Lyt 100, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Christopher C Korth: Innovator in Pulmonary Fibrosis Treatment
Introduction
Christopher C Korth is a notable inventor based in Rye, NH (US). He has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis (IPF). His innovative approach has the potential to improve the lives of many patients suffering from this challenging condition.
Latest Patents
Korth holds a patent for "Methods of treating idiopathic pulmonary fibrosis with deupirfenidone." This patent discloses a method of treating IPF by administering deuterium-enriched pirfenidone, known as LYT-100, at a total daily dose ranging from about 1650 mg to about 2500 mg. This advancement represents a promising step forward in the management of IPF.
Career Highlights
Christopher C Korth is associated with PureTech Lyt 100, Inc., where he continues to work on innovative solutions for pulmonary diseases. His dedication to research and development has positioned him as a key figure in the medical community.
Collaborations
Korth collaborates with talented professionals such as Varun Garg and Julie S Krop. Their combined expertise enhances the potential for groundbreaking advancements in the treatment of pulmonary conditions.
Conclusion
Christopher C Korth's work in developing methods for treating idiopathic pulmonary fibrosis showcases his commitment to innovation in medicine. His contributions are paving the way for improved therapeutic options for patients in need.